keyword
MENU ▼
Read by QxMD icon Read
search

Lanreotide

keyword
https://www.readbyqxmd.com/read/28540043/prescription-patterns-of-long-acting-somatostatin-analogues
#1
Jorge Enrique Machado-Alba, Manuel Enrique Machado-Duque
BACKGROUND: Acromegaly and endocrine tumors are uncommon morbidities that are currently treated with different drugs. OBJECTIVE: To determine the prescription patterns of somatostatin analogues in patients affiliated with the Health System of Colombia. METHODS: Retrospective cohort study of patients of any age and sex treated with octreotide or lanreotide between January 2011 and August 2015. Socio-demographic, clinical (indications) and pharmacological (comedications) variables were considered...
2017: SAGE Open Medicine
https://www.readbyqxmd.com/read/28507564/management-of-the-hormonal-syndrome-of-neuroendocrine-tumors
#2
Paweł Gut, Joanna Waligórska-Stachura, Agata Czarnywojtek, Nadia Sawicka-Gutaj, Maciej Bączyk, Katarzyna Ziemnicka, Jakub Fischbach, Kosma Woliński, Jarosław Kaznowski, Elżbieta Wrotkowska, Marek Ruchała
Gastroenteropancreatic neuroendocrine tumors (GEP/NET) are unusual and rare neoplasms that present many clinical challenges. They characteristically synthesize store and secrete a variety of peptides and neuroamines which can lead to the development of distinct clinical syndrome, however many are clinically silent until late presentation with mass effects. Management strategies include surgery cure and cytoreduction with the use of somatostatin analogues. Somatostatin have a broad range of biological actions that include inhibition of exocrine and endocrine secretions, gut motility, cell proliferation, cell survival and angiogenesis...
April 1, 2017: Archives of Medical Science: AMS
https://www.readbyqxmd.com/read/28506132/lanreotide-in-the-management-of-small-bowel-angioectasias-seven-year-data-from-a-tertiary-centre
#3
S Chetcuti Zammit, D S Sanders, R Sidhu
BACKGROUND AND AIMS: Haemorrhage from small bowel angioectasias (SBAs) can be debilitating to patients who are very often elderly and have multiple comorbidities. Our aim was to assess the use of lanreotide in addition to endotherapy in patients with SBAs. METHOD: Patients with SBAs on capsule endoscopy (CE) who received lanreotide injections from January 2010 to till the present day at the Royal Hallamshire Hospital in Sheffield were included. Baseline demographics were recorded...
May 16, 2017: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/28470558/phase-ii-study-of-lanreotide-autogel-in-japanese-patients-with-unresectable-or-metastatic-well-differentiated-neuroendocrine-tumors
#4
Tetsuhide Ito, Yoshitaka Honma, Susumu Hijioka, Atsushi Kudo, Akira Fukutomi, Akira Nozaki, Yasutoshi Kimura, Fuyuhiko Motoi, Hiroyuki Isayama, Izumi Komoto, Seiichi Hisamatsu, Akihiro Nakajima, Akira Shimatsu
Background Lanreotide is a long-acting somatostatin analog with demonstrated efficacy against enteropancreatic neuroendocrine tumor (NET) in the phase III (CLARINET) study. Materials and Methods In this single-arm study, Japanese patients with grade (G) 1/G2 NET received lanreotide (120 mg/4 weeks) for 48 weeks. Those who completed the study were enrolled in a long-term extension study. The primary endpoint was the clinical benefit rate (CBR) defined as a complete response, partial response (PR), or stable disease (SD) over 24-weeks...
May 3, 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/28430638/adjuvant-celecoxib-and-lanreotide-following-transarterial-chemoembolisation-for-unresectable-hepatocellular-carcinoma-a-randomized-pilot-study
#5
Huan Tong, Bo Wei, Shuang Chen, Yong-Mei Xie, Ming-Guang Zhang, Lin-Hao Zhang, Zhi-Yin Huang, Cheng-Wei Tang
Recurrence of hepatocellular carcinoma (HCC) after transarterial chemoembolisation (TACE) is common due to neoangiogenesis. Cyclooxygenase-2 inhibitors and somatostatin analogues were reported to inhibit tumour angiogenesis. The pilot randomized controlled trial was aimed to prospectively evaluate the protocol of TACE combined with celecoxib and lanreotide (TACE+C+L) in patients with unresectable and advanced HCC. A total of 71 patients with HCC were enrolled and randomly assigned to either TACE (n=35) or TACE+C+L (n=36) group...
February 24, 2017: Oncotarget
https://www.readbyqxmd.com/read/28419317/high-dose-and-high-frequency-lanreotide-autogel-in-acromegaly-a-randomized-multicenter-study
#6
Andrea Giustina, Gherardo Mazziotti, Salvatore Cannavò, Roberto Castello, Giorgio Arnaldi, Giovanna Bugari, Renato Cozzi, Diego Ferone, Anna Maria Formenti, Enza Gatti, Silvia Grottoli, Pietro Maffei, Filippo Maffezzoni, Marcella Montini, Massimo Terzolo, Ezio Ghigo
Context: The increase in drug frequency or dose is recommended for acromegaly patients with partial response to long-acting somatostatin receptor ligands (SRLs). However, the efficacy and safety data with lanreotide autogel (LAN-ATG) at high-dose (HD) or high-frequency (HF) are still scanty and anecdotal. Objective: To evaluate the biochemical efficacy and safety of HF- and HD LAN-ATG in patients with active acromegaly. Design: 24-week prospective, multicentre, randomized, open-label trial...
April 17, 2017: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28390105/marked-alteration-of-glycemic-profile-surrounding-lanreotide-administration-in-acromegaly-a-case-report
#7
Sho Tanaka, Akira Haketa, Shun Yamamuro, Toshiko Suzuki, Hiroki Kobayashi, Yoshinari Hatanaka, Takahiro Ueno, Noboru Fukuda, Masanori Abe, Atsuo Yoshino, Masayoshi Soma
Whether somatostatin analogs for acromegaly improve or worsen a patient's glycemic profile is controversial. A risk of hypoglycemia should be presumed especially when patients receive insulin therapy, as the package inserts caution. However, a detailed clinical course of such a case was never reported in research articles. An 80-year-old Japanese female diabetic treated with insulin therapy was diagnosed with acromegaly, and the somatostatin analog, lanreotide, was administered. On day 4 of administration, repeated hypoglycemia due to exogenous insulin arose and the patient required inpatient care...
April 8, 2017: Journal of Diabetes Investigation
https://www.readbyqxmd.com/read/28375946/antisecretory-effects-of-chimeric-somatostatin-dopamine-receptor-ligands-on-gastroenteropancreatic-neuroendocrine-tumors
#8
Anne Couvelard, Didier Pélaprat, Safi Dokmak, Alain Sauvanet, Thierry Voisin, Alain Couvineau, Philippe Ruszniewski
OBJECTIVES: The recent finding that gastroenteropancreatic neuroendocrine tumors expressed the dopaminergic D2 receptor in addition to somatostatin (sst) receptors suggested that multiple targeting approaches might decrease hormone hypersecretion more effectively than sst agonists alone. METHODS: To test this hypothesis, (i) we measured the expression of sst receptor type 2 (sst2 receptor) and D2 receptor in 11 gastroenteropancreatic neuroendocrine tumors and (ii) we compared the ability of lanreotide, cabergoline, their combination, and sst/D2 chimeric ligands to decrease chromogranin A (CgA), gastrin, or serotonin release in primary cultures derived from these tumors...
May 2017: Pancreas
https://www.readbyqxmd.com/read/28372573/treatment-adherence-and-persistence-with-long-acting-somatostatin-analog-therapy-for-the-treatment-of-acromegaly-a-retrospective-analysis
#9
Michelle H Gurel, Yi Han, Andrea L Stevens, Aaron Furtado, David Cox
BACKGROUND: Many patients with acromegaly require medical treatment that includes somatostatin analogs (SSAs). Long-acting SSA formulations are widely used, due in part to increased patient convenience and increased treatment adherence vs daily medications. Although medication compliance can be poor in patients with chronic conditions, adherence and persistence with these SSAs in patients with acromegaly has not been evaluated. This analysis utilized claims data to estimate treatment adherence and persistence for lanreotide depot and long-acting octreotide in this population...
April 4, 2017: BMC Pharmacology & Toxicology
https://www.readbyqxmd.com/read/28316591/predictors-of-quality-of-life-in-acromegaly-no-consensus-on-biochemical-parameters
#10
REVIEW
Victor J Geraedts, Cornelie D Andela, Günter K Stalla, Alberto M Pereira, Wouter R van Furth, Caroline Sievers, Nienke R Biermasz
BACKGROUND: Quality of life (QoL) in patients with acromegaly is reduced irrespective of disease state. The contributions of multifactorial determinants of QoL in several disease stages are presently not well known. OBJECTIVE: To systematically review predictors of QoL in acromegalic patients. METHODS: Main databases were systematically searched using predefined search terms for potentially relevant articles up to January 2017. Inclusion criteria included separate acromegaly cohort, non-hereditary acromegaly, QoL as study parameter with clearly described method of measurement and quantitative results, N ≥ 10 patients, article in English and adult patients only...
2017: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/28316158/-cost-effectiveness-analysis-of-octreotide-long-acting-release-and-lanreotide-slow-release-for-the-treatment-of-postoperative-patients-with-active-acromegaly-in-china
#11
J W Xuan, Z Y Zhang, Y F Wang, Z G Mao, Y J Lu, R Z Wang
Objective: To evaluate the cost-effectiveness of octreotide long acting release (LAR) vs lanreotide slow release (SR) for the treatment of postoperative acromegalic patients with elevated levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) in China. Methods: A decision tree model was constructed and the treatment impact was projected for one year in Chinese setting. The clinical efficacy measure used was the percentage of patients achieving normalization (control) of either IGF-1 or GH levels...
March 14, 2017: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/28292641/evaluating-lanreotide-as-maintenance-therapy-after-first-line-treatment-in-patients-with-non-resectable-duodeno-pancreatic-neuroendocrine-tumours
#12
Côme Lepage, Laetitia Dahan, Nadia Bouarioua, Christos Toumpanakis, Jean-Louis Legoux, Karine Le Malicot, Rosine Guimbaud, Denis Smith, David Tougeron, Astrid Lievre, Guillaume Cadiot, Frédéric Di Fiore, Karine Bouhier-Leporrier, Olivia Hentic, Roger Faroux, Marianne Pavel, Ivan Borbath, Juan W Valle, Anja Rinke, Jean-Yves Scoazec, Michel Ducreux, Thomas Walter
INTRODUCTION: Patients with metastatic or locally advanced, non-resectable, grade 1 or 2 well-differentiated duodeno-pancreatic (WDDP) NETs are treated following European guidelines. Patients (Pts) with aggressive disease, i.e. progressive and/or symptomatic metastases and/or with significant hepatic invasion (>30-50%), and/or bone metastases, anti-tumour therapy should receive systemic combination of chemotherapy once disease control is obtained. AIM(S): The aim is to stop chemotherapy until progression...
March 11, 2017: Digestive and Liver Disease
https://www.readbyqxmd.com/read/28220021/the-antiproliferative-role-of-lanreotide-in-controlling-growth-of-neuroendocrine-tumors-a-systematic-review
#13
REVIEW
Michael Michael, Rocio Garcia-Carbonero, Matthias M Weber, Catherine Lombard-Bohas, Christos Toumpanakis, Rodney J Hicks
BACKGROUND: Neuroendocrine tumors (NETs) are a heterogeneous group of tumors, with >50% of cases involving the gastrointestinal system or pancreas. Somatostatin analogs (SSAs) are used for treating NET-related secretory syndromes and, more recently, for their antiproliferative effects. We conducted a systematic review of published literature on the antiproliferative efficacy and safety of the SSA lanreotide Autogel in the management of NETs to gain a fuller understanding of the evidence and identify future areas of research...
March 2017: Oncologist
https://www.readbyqxmd.com/read/28176162/somatostatin-receptor-ligands-in-the-treatment-of-acromegaly
#14
REVIEW
Monica R Gadelha, Luiz Eduardo Wildemberg, Marcello D Bronstein, Federico Gatto, Diego Ferone
First-generation somatostatin receptors ligands (SRL) are the mainstay in the medical treatment of acromegaly, however the percentage of patients controlled with these drugs significantly varies in the different studies. Many factors are involved in the resistance to SRL. In this review, we update the physiology of somatostatin and its receptors (sst), the use of SRL in the treatment of acromegaly and the factors involved in the response to these drugs. The SRL act through interaction with the sst, which up to now have been characterized as five subtypes...
February 2017: Pituitary
https://www.readbyqxmd.com/read/28091879/new-medical-therapies-on-the-horizon-oral-octreotide
#15
REVIEW
Nienke R Biermasz
Somatostatin analog treatment is first line medical treatment in patients with acromegaly. This drug is currently mainly administered by monthly depot preparations of octreotide and lanreotide. With the innovative transient permeability enhancer, a technology enabling the absorption of drug molecules via transient opening of the tight junctions of the gut epithelium, it is possible to achieve therapeutic octreotide levels after oral ingestion. The present review summarized the preclinical work and the recently reported phase I and III study on oral octreotide capsules in patients with acromegaly...
February 2017: Pituitary
https://www.readbyqxmd.com/read/28008238/communication-practices-and-awareness-of-resources-for-acromegaly-patients-among-endocrinologists
#16
Susan Polanco-Briceno, Daniel Glass, Cindy Plunkett
PURPOSE: This study was designed to assess the awareness and utilization of resources to improve patients' treatment experiences among endocrinologists who currently treat patients with acromegaly. METHODS: A total of 4,280 US endocrinologists were randomly selected from the CMS National Plan and Provider Enumeration System and were invited by mail to participate in a 20-minute online survey. In order to qualify, respondents had to be the primary physician making treatment decisions for at least one patient for their acromegaly...
2016: Patient Preference and Adherence
https://www.readbyqxmd.com/read/27995519/hepatic-cyst-infection-during-use-of-the-somatostatin-analog-lanreotide-in-autosomal-dominant-polycystic-kidney-disease-an-interim-analysis-of-the-randomized-open-label-multicenter-dipak-1-study
#17
Marten A Lantinga, Hedwig M A D'Agnolo, Niek F Casteleijn, Johan W de Fijter, Esther Meijer, Annemarie L Messchendorp, Dorien J M Peters, Mahdi Salih, Edwin M Spithoven, Darius Soonawala, Folkert W Visser, Jack F M Wetzels, Robert Zietse, Joost P H Drenth, Ron T Gansevoort
INTRODUCTION AND AIMS: The DIPAK-1 Study investigates the reno- and hepatoprotective efficacy of the somatostatin analog lanreotide compared with standard care in patients with later stage autosomal dominant polycystic kidney disease (ADPKD). During this trial, we witnessed several episodes of hepatic cyst infection, all during lanreotide treatment. We describe these events and provide a review of the literature. METHODS: The DIPAK-1 Study is an ongoing investigator-driven, randomized, controlled, open-label multicenter trial...
February 2017: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://www.readbyqxmd.com/read/27972489/dose-extension-and-costs-of-lanreotide-autogel-120-mg-used-in-routine-neuroendocrine-tumors-care-in-poland-2-years-data-from-lanro-net-study
#18
E Orlewska, T Bednarczuk, G Kaminski, T Budlewski, B Kos-Kudla
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27972405/evaluation-of-injectable-lanreotide-acetate-in-the-treatment-of-liver-carcinoma
#19
T R Nunes, D C Viana, M R Galdino-Pitta, P S Oliveira, M S Landim, P R Cardoso, M J Rego, F Zanghelini, M D Oliveira, C A Andrade, M G Pitta
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27972167/budget-impact-analysis-of-lanreotide-autogel-120-mg-in-the-treatment-of-acromegaly-in-poland
#20
E Orlewska, B Kos-Kudla, J Sowinski, K Sworczak, W Zgliczynski
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
keyword
keyword
81166
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"